NZ330596A
(en)
|
1998-06-05 |
2001-02-23 |
Dec Res |
Intravaginal devices allowing for increased uptake of active ingredients
|
US7588793B1
(en)
|
1998-06-05 |
2009-09-15 |
Cadbury Adams Usa, Llc |
Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
|
PT1140105E
(pt)
*
|
1998-12-24 |
2004-03-31 |
Janssen Pharmaceutica Nv |
Composicao de galantamina de libertacao controlada
|
EP1027885B1
(fr)
*
|
1999-02-09 |
2008-07-09 |
Pfizer Products Inc. |
Compositions de médicaments basiques avec une meilleure biodisponibilité
|
DE60023465T2
(de)
|
1999-03-24 |
2006-07-20 |
R.P. Scherer Technologies, Inc., Las Vegas |
Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
WO2001002393A1
(fr)
*
|
1999-07-01 |
2001-01-11 |
Italfarmaco S.P.A. |
Complexes de paroxetine, avec des cyclodextrines et des derives de la cyclodextrine
|
AU5975700A
(en)
*
|
1999-07-02 |
2001-01-22 |
Janssen Pharmaceutica N.V. |
Nasal formulation of an antifungal
|
CA2315614C
(fr)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
US6835717B2
(en)
|
2000-03-08 |
2004-12-28 |
The Johns Hopkins University School Of Medicine |
β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
|
BR0110530A
(pt)
|
2000-05-02 |
2003-04-08 |
Theravance Inc |
Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
DE60102233T2
(de)
|
2000-05-26 |
2005-01-27 |
Pfizer Inc. |
Triazolyltropanderivate als ccr5-modulatoren
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
CN1322850C
(zh)
*
|
2000-06-02 |
2007-06-27 |
沈阳药科大学 |
盐酸尼卡地平粉针剂及其制备方法
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
GB0015239D0
(en)
*
|
2000-06-21 |
2000-08-16 |
Biochemie Gmbh |
Organic compounds
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
PE20020300A1
(es)
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
CA2432319A1
(fr)
|
2000-12-21 |
2002-07-18 |
Nektar Therapeutics |
Apport pulmonaire d'agents antifongiques polyene
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
DE60219292T2
(de)
|
2001-04-10 |
2008-04-10 |
Pfizer Inc. |
Pyrazolderivate zur behandlung von hiv
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
FR2827516B1
(fr)
*
|
2001-07-19 |
2003-09-19 |
Servier Lab |
Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
CN101259289B
(zh)
*
|
2001-11-02 |
2012-05-30 |
嵌入治疗公司 |
用于rna干扰的治疗用途的方法及组合物
|
CA2363376A1
(fr)
*
|
2001-11-16 |
2003-05-16 |
Bernard Charles Sherman |
Compositions pharmaceutiques solides, comprenant de l'itraconazole, destinees a l'administration orale
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
RS70104A
(en)
|
2002-02-11 |
2007-02-05 |
Pfizer Limited, |
Nicotinamide derivatives useful as pde4 inhibitors
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US8128957B1
(en)
|
2002-02-21 |
2012-03-06 |
Valeant International (Barbados) Srl |
Modified release compositions of at least one form of tramadol
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
CN100518831C
(zh)
*
|
2002-08-15 |
2009-07-29 |
刘云清 |
固体纳米药物及其制备方法
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
KR20050046776A
(ko)
*
|
2002-09-13 |
2005-05-18 |
사이덱스 인크 |
유도체화된 사이클로덱스트린으로 안정화한 수성 충전조성물을 포함하는 캅셀
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
CA2451267A1
(fr)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Utilisations pharmaceutiques de ligands alpha2delta
|
CA2509605C
(fr)
|
2002-12-13 |
2010-10-05 |
Warner-Lambert Company Llc |
Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
|
US7993654B2
(en)
*
|
2002-12-23 |
2011-08-09 |
Beiersdorf Ag |
Self-adhesive polymer matrix containing sea algae extract
|
DE10260872B4
(de)
|
2002-12-23 |
2013-09-26 |
Beiersdorf Ag |
Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
|
DE10260873A1
(de)
|
2002-12-23 |
2004-07-15 |
Beiersdorf Ag |
Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
|
EP1653929A1
(fr)
*
|
2003-01-22 |
2006-05-10 |
Sandoz AG |
Composition pharmaceutique solide comprenant du ramipril
|
MXPA05008718A
(es)
*
|
2003-02-17 |
2005-09-20 |
Sun Pharmaceutical Ind Ltd |
Una composicion de corticosteroide de dosis baja.
|
EP1460064A1
(fr)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Derivés de Indole-2-carboxamide comme beta-2 agonistes
|
ES2584183T3
(es)
|
2003-03-28 |
2016-09-26 |
Ares Trading S.A. |
Formulaciones de cladribina para suministro mejorado oral y transmucosa
|
PT1608344E
(pt)
*
|
2003-03-28 |
2010-09-02 |
Ares Trading Sa |
Formulações orais de cladribina
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
DE10338544B4
(de)
*
|
2003-08-19 |
2017-08-31 |
Janssen Pharmaceutica N.V. |
Buccale Formulierungen des Galanthamins und deren Anwendungen
|
JP2007504266A
(ja)
*
|
2003-09-02 |
2007-03-01 |
ファイザー・プロダクツ・インク |
ジプラシドンの持続放出剤形
|
KR100738784B1
(ko)
|
2003-09-03 |
2007-07-12 |
화이자 인코포레이티드 |
5-ht4 수용체 효능 활성을 갖는 벤즈이미다졸론
|
ES2335284T3
(es)
|
2003-09-03 |
2010-03-24 |
Glaxo Group Limited |
Nuevo procedimiento para preparar derivados de pleuromutilina.
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
MXPA06002789A
(es)
|
2003-09-12 |
2006-06-14 |
Pfizer |
Combinaciones que comprenden ligandos alfa-2-delta.
|
AP2174A
(en)
|
2003-10-03 |
2010-11-20 |
Pfizer |
Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US8597703B2
(en)
|
2005-05-23 |
2013-12-03 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
|
US8591968B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Edible composition including a delivery system for active components
|
US8591974B2
(en)
|
2003-11-21 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for two or more active components as part of an edible composition
|
US20050112236A1
(en)
|
2003-11-21 |
2005-05-26 |
Navroz Boghani |
Delivery system for active components as part of an edible composition having preselected tensile strength
|
ZA200604253B
(en)
|
2003-11-21 |
2007-10-31 |
Combinatorx Inc |
Methods and reagents for the treatment of inflammatory disorders
|
US8389032B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition having selected particle size
|
US9271904B2
(en)
|
2003-11-21 |
2016-03-01 |
Intercontinental Great Brands Llc |
Controlled release oral delivery systems
|
US8591973B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
|
US8591972B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for coated active components as part of an edible composition
|
US8389031B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Coated delivery system for active components as part of an edible composition
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
DK1708992T3
(da)
|
2004-01-22 |
2007-11-05 |
Pfizer |
Sulfonamidderivater til behandling af sygdomme
|
NZ548318A
(en)
|
2004-01-22 |
2009-03-31 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP1735284A1
(fr)
|
2004-03-18 |
2006-12-27 |
Pfizer Limited |
Sulfamides n-(1-arylpyrazol-4l) et leur utilisation en tant qu'anti-parasitaires
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
BRPI0507877A
(pt)
|
2004-03-23 |
2007-07-24 |
Pfizer |
derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
|
KR100479367B1
(ko)
*
|
2004-04-13 |
2005-03-29 |
(주) 에프디엘 |
이트라코나졸을 포함하는 경구투여용 항진균제 조성물
|
AP2006003771A0
(en)
|
2004-04-30 |
2006-10-31 |
Warner Lambert Co |
Substituted morpholine compounds for the treatmentof central nervous system disorders
|
BRPI0509592A
(pt)
*
|
2004-05-06 |
2007-09-25 |
Cydex Inc |
formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
EP1595881A1
(fr)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
MXPA06014486A
(es)
|
2004-06-15 |
2007-03-01 |
Pfizer |
Derivados de acido carboxilico de bencimidazolona.
|
US20050282895A1
(en)
*
|
2004-06-21 |
2005-12-22 |
Dosch Michael H |
Antimicrobial compositions and methods of use thereof
|
WO2006020686A1
(fr)
*
|
2004-08-11 |
2006-02-23 |
Cadbury Adams Usa Llc |
Compositions de rechauffement et systemes de liberation associes
|
DK1778686T3
(da)
|
2004-08-12 |
2009-01-12 |
Pfizer |
Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
|
US7955630B2
(en)
*
|
2004-09-30 |
2011-06-07 |
Kraft Foods Global Brands Llc |
Thermally stable, high tensile strength encapsulated actives
|
US20060068058A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Cadbury Adams Usa Llc |
Thermally stable, high tensile strength encapsulation compositions for actives
|
US7727565B2
(en)
|
2004-08-25 |
2010-06-01 |
Cadbury Adams Usa Llc |
Liquid-filled chewing gum composition
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
CN1325054C
(zh)
*
|
2004-09-29 |
2007-07-11 |
南京师范大学 |
盐酸哌唑嗪的环糊精包合物及其制备方法
|
DE602005011844D1
(de)
|
2004-11-02 |
2009-01-29 |
Pfizer |
Sulfonylbenzimidazolderivate
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
JP4335120B2
(ja)
|
2004-11-08 |
2009-09-30 |
カゴメ株式会社 |
混合飲料の製造方法
|
US9198448B2
(en)
*
|
2005-02-07 |
2015-12-01 |
Intercontinental Great Brands Llc |
Stable tooth whitening gum with reactive ingredients
|
CA2614223A1
(fr)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
Procede d'enregistrement et systeme de controle pour medicaments des listes ii-v de la drug enforcement agency (dea)
|
KR100927915B1
(ko)
|
2005-03-17 |
2009-11-19 |
화이자 인코포레이티드 |
통증 치료에 유용한 n-(n-설폰일아미노메틸)사이클로프로판카복사마이드 유도체
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
EP1874331B1
(fr)
|
2005-04-19 |
2014-09-03 |
Kings College London |
Utilisation de la bip contre la perte des os et l'osteoporose
|
AU2006239941A1
(en)
*
|
2005-04-24 |
2006-11-02 |
Wyeth |
Methods for modulating bladder function
|
WO2006117670A1
(fr)
|
2005-05-04 |
2006-11-09 |
Pfizer Limited |
Derives de 2-amido-6-amino-8-oxopurine en tant que modulateurs du recepteur du type toll pour le traitement du cancer et d'infections virales, telles que l'hepatite c
|
JP4750184B2
(ja)
|
2005-05-23 |
2011-08-17 |
キャドバリー アダムス ユーエスエー エルエルシー |
味覚増強組成物並びに味覚増強組成物を含有する、食用菓子製品及びチューインガム製品
|
US7851006B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
US7851005B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
ES2277743B2
(es)
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
EA200702497A1
(ru)
|
2005-06-15 |
2008-06-30 |
Пфайзер Лимитед |
Замещенные арилпиразолы для применения против паразитов
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070221236A1
(en)
*
|
2005-10-05 |
2007-09-27 |
Cadbury Adams Usa Llc. |
Cooling compositions including menthyl esters
|
CN100503647C
(zh)
*
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
AU2006318349B2
(en)
*
|
2005-11-28 |
2010-08-19 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
EP1973422B1
(fr)
*
|
2005-12-23 |
2014-06-11 |
Intercontinental Great Brands LLC |
Compositions donnant une sensation de chaud pour prise orale ou application dermique
|
US20070148283A1
(en)
*
|
2005-12-23 |
2007-06-28 |
Cadbury Adams Usa Llc |
Compositions providing a sensation substantially similar to that provided by menthol
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
AR060090A1
(es)
*
|
2006-03-24 |
2008-05-21 |
Wyeth Corp |
Metodos para tratar trastornos cognitivos y otros afines
|
EP1998773A2
(fr)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
|
EP1998782A2
(fr)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Méthodes pour moduler la fonction de la vessie
|
PE20080126A1
(es)
*
|
2006-03-24 |
2008-04-07 |
Wyeth Corp |
Metodos para tratar trastornos cognitivos y otros afines
|
EP1998781A2
(fr)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Traitement de la douleur
|
KR100917809B1
(ko)
*
|
2006-05-22 |
2009-09-18 |
에스케이케미칼주식회사 |
우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
|
WO2008012538A2
(fr)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Souche de vaccin vivant
|
EP2061459B1
(fr)
|
2006-08-23 |
2012-12-26 |
Intellect Neurosciences Inc. |
Sel de calcium de l'acide 3-(3-indolyl)propionique et méthode de fabrication de l'acide libre de l'acide 3-(3-indolyl)propionique à partir dudit sel
|
US9744137B2
(en)
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
WO2008031439A2
(fr)
|
2006-09-15 |
2008-03-20 |
Stevia Aps |
Traitement de la résistance à l'insuline ou de maladies associées à la résistance à l'insuline
|
RU2412188C2
(ru)
|
2006-09-21 |
2011-02-20 |
Раквалиа Фарма Инк. |
Производные бензимидазола в качестве селективных ингибиторов кислотной помпы
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
PT2076508E
(pt)
|
2006-10-18 |
2011-03-07 |
Pfizer Prod Inc |
Compostos de ureia de éter biarílico
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
CA2666317C
(fr)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Substances inhibant la glycolyse dans une culture de cellules
|
AU2007319141B2
(en)
|
2006-11-17 |
2013-01-10 |
Supernus Pharmaceuticals Inc. |
Sustained-release formulations of topiramate
|
BRPI0717721A2
(pt)
|
2006-11-28 |
2013-10-29 |
Marinus Pharmaceuticals |
"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
|
MX2009003911A
(es)
*
|
2006-12-04 |
2009-05-28 |
Supernus Pharmaceuticals Inc |
Formulaciones de liberacion inmediata, mejoradas de topiramato.
|
CA2677365A1
(fr)
|
2007-02-06 |
2008-08-14 |
Pfizer Inc. |
Derives de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine en tant qu'inhibiteurs de la hsp 90 pour le traitement du cancer
|
AU2008223133A1
(en)
|
2007-03-02 |
2008-09-12 |
Wyeth |
Use of copper and glutamate in cell culture for production of polypeptides
|
EP2160381A2
(fr)
*
|
2007-05-24 |
2010-03-10 |
Pfizer Limited |
Dérivés spirocycliques de quinazoline et leur utilisation comme inhibiteurs de pde7
|
WO2008147556A2
(fr)
|
2007-05-25 |
2008-12-04 |
Ipsen Pharma S.A.S. |
Ligands de récepteurs de la mélanocortine modifiés au moyen d'hydantoïne
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
RU2458925C2
(ru)
|
2007-09-05 |
2012-08-20 |
Райджел Фармасьютикалз, Инк. |
Ксинафоатная соль n4-[(2,2-дифтор-4н-бензо[1,4]оксазин-3-он)-6-ил]-5-фтор-n2-[3-(метиламинокарбонилметиленокси)фенил]-2,4-пиримидиндиамина
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
WO2009067587A1
(fr)
*
|
2007-11-20 |
2009-05-28 |
Cadbury Adams Usa Llc |
Produit de confiserie à double enrobage
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US20090275622A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Prasoona Linga |
Nizatidine formulations
|
DK2313111T3
(da)
*
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-lignende receptoragonistformuleringer og anvendelse deraf
|
EP2328890B1
(fr)
|
2008-08-06 |
2012-01-25 |
Pfizer Inc. |
Composés 2-hétérocyclylamino pyrazines substituées en position 6 en tant qu'inhibiteurs de chk-1
|
EP2163253B1
(fr)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extraits de la plante Hornstedtia scyphifera et ses effets immunosuppresseurs
|
WO2010058858A1
(fr)
|
2008-11-21 |
2010-05-27 |
ラクオリア創薬株式会社 |
Nouveau dérivé de pyrazole-3-carboxamide doté d’une activité antagoniste du récepteur 5-ht2b
|
KR101128450B1
(ko)
*
|
2008-12-11 |
2012-03-28 |
(주)바이오제닉스 |
안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
BRPI1006128A2
(pt)
|
2009-01-12 |
2016-11-01 |
Cagen Inc |
derivados de sulfonamida
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
EA021683B1
(ru)
|
2009-01-14 |
2015-08-31 |
Новакта Биосистемс Лимитед |
Производные деоксиактагардина в
|
NZ594675A
(en)
|
2009-02-04 |
2013-11-29 |
Novacta Biosystems Ltd |
Actagardine derivatives
|
CN102369212B
(zh)
|
2009-03-12 |
2015-12-16 |
哈瑟投资公司 |
具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体
|
EP2233502A1
(fr)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Anticorps spécifiques à l'antigène syalilé pour le traitement ou prophylaxie des réactions immunitaires inflammatoires non désirables et leurs procédés de production
|
WO2010116270A1
(fr)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Agonistes de ep2/4
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US20100291201A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Cerovene, Inc. |
Coated pharmaceutical capsule dosage form
|
EP2435462A1
(fr)
|
2009-05-29 |
2012-04-04 |
Pfizer Limited |
Nouveaux agonistes du récepteur des glucocorticoïdes
|
EP2266563A1
(fr)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Utilisation d'antagonistes de récepteur opioïde pour le traitement aigu des états d'éveil paraphiliques
|
WO2011004276A1
(fr)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Inhibiteurs du virus de lhépatite c
|
US8691809B2
(en)
|
2009-08-18 |
2014-04-08 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
RU2580320C2
(ru)
|
2009-08-18 |
2016-04-10 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
WO2011077313A1
(fr)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Pipéridinecarboxamides en tant qu'inhibiteurs de mpges - 1
|
PL2516434T3
(pl)
|
2009-12-23 |
2015-11-30 |
Takeda Pharmaceuticals Co |
Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK
|
WO2011083387A1
(fr)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Sel de chlorhydrate du biphényl-2-yl-carbamate de 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-méthyl-amino]-nonyl}-pipéridin-4-yle
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
CA2789164A1
(fr)
|
2010-02-02 |
2011-08-11 |
Novacta Biosystems Limited |
Sels
|
CA2789606A1
(fr)
|
2010-02-25 |
2011-09-01 |
Pfizer Limited |
Analogues peptidiques en tant qu'agonistes des recepteurs opioides
|
WO2011138751A2
(fr)
|
2010-05-04 |
2011-11-10 |
Pfizer Inc. |
Dérivés hétérocycliques destinés au traitement de maladies
|
WO2011154871A1
(fr)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Inhibiteurs du virus de l'hépatite c
|
US9145407B2
(en)
|
2010-07-09 |
2015-09-29 |
Pfizer Limited |
Sulfonamide compounds
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドPfizer Limited |
化合物
|
US9096558B2
(en)
|
2010-07-09 |
2015-08-04 |
Pfizer Limited |
N-sulfonylbenzamide compounds
|
EP2593432B1
(fr)
|
2010-07-12 |
2014-10-22 |
Pfizer Limited |
Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant
|
EP2593431B1
(fr)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
|
US8772343B2
(en)
|
2010-07-12 |
2014-07-08 |
Pfizer Limited |
Chemical compounds
|
ES2532357T3
(es)
|
2010-07-12 |
2015-03-26 |
Pfizer Limited |
Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
|
CA2804716A1
(fr)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Composes chimiques
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
US20130225523A1
(en)
|
2010-08-24 |
2013-08-29 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
WO2012042421A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Procédé de traitement de la croissance cellulaire anormale
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
WO2012066442A1
(fr)
|
2010-11-15 |
2012-05-24 |
Pfizer Limited |
Inhibiteurs de la réplication du vih
|
WO2012095781A1
(fr)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Dérivés d'indazole comme inhibiteurs des canaux sodiques
|
AR085406A1
(es)
|
2011-02-25 |
2013-09-25 |
Takeda Pharmaceutical |
Oxazinopteridinas y oxazinopteridinonas n-sustituidas
|
WO2012120398A1
(fr)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
|
CN102139115B
(zh)
*
|
2011-03-30 |
2012-12-05 |
天津红日药业股份有限公司 |
阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
|
BR112013025792A2
(pt)
|
2011-04-05 |
2018-04-24 |
Pfizer Ltd |
Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
|
WO2012157288A1
(fr)
|
2011-05-18 |
2012-11-22 |
Raqualia Pharma Inc. |
Forme polymorphe de l'acide 4-{[4-({[4-(2,2,2-trifluoroéthoxy)- 1,2-benzisoxazol-3-yl]oxy}méthyl)pipéridin-1-yl]méthyl}-tétrahydro-2h- pyran-4-carboxylique
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
US9056873B2
(en)
|
2011-06-22 |
2015-06-16 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
US8957025B2
(en)
|
2011-07-13 |
2015-02-17 |
Pfizer Inc. |
Enkephalin analogues
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
KR20140041906A
(ko)
|
2011-08-02 |
2014-04-04 |
화이자 인코포레이티드 |
암의 치료에 사용하기 위한 크리조티닙
|
EP2739274A1
(fr)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Traitement d'un trouble cognitif
|
WO2013054185A1
(fr)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Dérivés de pyrimidine et de pyridine utiles en thérapie
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
EP2771335A2
(fr)
|
2011-10-26 |
2014-09-03 |
Pfizer Limited |
Composés chimiques
|
CN106220572B
(zh)
|
2011-10-28 |
2019-12-13 |
因西必泰克新有限公司 |
哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法
|
EP2791108B1
(fr)
|
2011-12-15 |
2016-07-27 |
Pfizer Limited |
Dérivés sulfonamides
|
WO2013093688A1
(fr)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
|
WO2013102826A1
(fr)
|
2012-01-04 |
2013-07-11 |
Pfizer Limited |
N-aminosulfonylbenzamides
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
CA2861439C
(fr)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Derives d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium
|
TW201336527A
(zh)
*
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
DK2822953T5
(en)
|
2012-03-06 |
2017-09-11 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
WO2013148603A1
(fr)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Dérivés de cinnoline en tant qu'en tant qu'inhibiteurs de la btk
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
MA37753B1
(fr)
*
|
2012-07-12 |
2019-04-30 |
Sanofi Sa |
Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée
|
IN2014KN02981A
(fr)
*
|
2012-07-17 |
2015-05-08 |
Glaxosmithkline Llc |
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
JP6463680B2
(ja)
|
2012-09-18 |
2019-02-06 |
ジアルコ ファーマ リミテッドZiarco Pharma Ltd |
脾臓チロシンキナーゼi(syk)阻害剤としての2−(2−アミノシクロヘキシル)アミノピリミジン−5−カルボキサミド類
|
US20150239842A1
(en)
|
2012-09-28 |
2015-08-27 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
CA2885247A1
(fr)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Inhibiteurs de kinases apparentes a la tropomyosine
|
US9163021B2
(en)
|
2012-10-04 |
2015-10-20 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
JP2015531394A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
ピロロ[2,3−d]ピリミジントロポミオシン関連キナーゼ阻害剤
|
BR112015010412A2
(pt)
|
2012-11-08 |
2017-07-11 |
Pfizer |
compostos heteroaromáticos e seu uso como ligantes de dopamina d1
|
JP5857168B2
(ja)
|
2012-11-08 |
2016-02-10 |
ファイザー・インク |
ドーパミンd1リガンドとしての複素芳香族化合物およびその使用
|
US10179779B2
(en)
|
2012-11-21 |
2019-01-15 |
Raqualia Pharma Inc. |
Polymorph forms
|
NZ707752A
(en)
|
2012-12-03 |
2020-01-31 |
Pfizer |
Novel selective androgen receptor modulators
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
PL3431475T3
(pl)
|
2013-02-21 |
2021-09-13 |
Pfizer Inc. |
Stałe postacie selektywnego inhibitora CDK4/6
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
EP2784083A1
(fr)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Variantes de protéine morphogénétique osseuse (BMP) avec sensibilité antagoniste fortement réduite et meilleure activité biologique spécifique
|
EP2792360A1
(fr)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(fr)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Forme cristalline de (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
DK3013813T3
(da)
|
2013-06-27 |
2019-06-03 |
Pfizer |
Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
|
WO2015006219A1
(fr)
|
2013-07-08 |
2015-01-15 |
Abbvie, Inc. |
Formes pharmaceutiques stabilisées comprenant de l'atrasentan
|
CN113181110A
(zh)
*
|
2013-07-19 |
2021-07-30 |
勃林格殷格翰动物保健有限公司 |
含有防腐的醚化的环糊精衍生物的液体水性药物组合物
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
JP2016540811A
(ja)
|
2013-12-20 |
2016-12-28 |
ファイザー・リミテッドPfizer Limited |
N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
|
WO2015106014A1
(fr)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Dérivés d'azaindole
|
UY35945A
(es)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
Derivados de azaindol
|
WO2015157509A1
(fr)
*
|
2014-04-10 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Compositions et methodes de traitement de maladies associées aux recepteurs des opioides
|
WO2015159175A1
(fr)
|
2014-04-15 |
2015-10-22 |
Pfizer Inc. |
Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine
|
WO2015162515A1
(fr)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
|
MA39914A
(fr)
|
2014-04-25 |
2017-03-01 |
Pfizer |
Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
WO2015166370A1
(fr)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
|
EP3137469B1
(fr)
|
2014-04-28 |
2019-10-09 |
Pfizer Inc |
Composés hétérocycliques et leur utilisation comme ligands des récepteurs d1 de la dopamine
|
EP3140298A1
(fr)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Inhibiteurs de kinases apparentées à la tropomyosine
|
KR20170002623A
(ko)
|
2014-05-14 |
2017-01-06 |
화이자 인코포레이티드 |
피라졸로피리딘 및 피라졸로피리미딘
|
US9920043B2
(en)
|
2014-05-15 |
2018-03-20 |
Pfizer Inc. |
Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile
|
MX366985B
(es)
|
2014-05-20 |
2019-08-01 |
Raqualia Pharma Inc |
Sales derivadas de bencisoxazol.
|
WO2015181797A1
(fr)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
|
WO2015181676A1
(fr)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
|
JP6491679B2
(ja)
|
2014-06-12 |
2019-03-27 |
ファイザー・リミテッドPfizer Limited |
Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
|
MD4820C1
(ro)
|
2014-06-17 |
2023-03-31 |
Pfizer Inc. |
Compuşi dihidroizochinolinonici substituiţi
|
WO2015193768A1
(fr)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
|
WO2016009296A1
(fr)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
|
WO2016009303A1
(fr)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7
|
WO2016009297A1
(fr)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Dérivés de la pyridine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
|
WO2016020784A1
(fr)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
|
WO2016034971A1
(fr)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Dérivés sulfonamides utilisés en tant qu'inhibiteurs d'urat1
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(fr)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
Composés n- (2-alkylèneimino-3-phénylpropyl)acétamide et leur utilisation contre la douleur et le prurit par inhibition des canaux trpa1
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
PT3247371T
(pt)
|
2015-01-22 |
2020-07-02 |
Phytoplant Res S L |
Métodos de purificação de canabinóides, composições e kits associados
|
ES2764840T3
(es)
|
2015-01-28 |
2020-06-04 |
Univ Bordeaux |
Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
|
MX2017010844A
(es)
|
2015-02-24 |
2017-12-07 |
Pfizer |
Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
|
CA2979527A1
(fr)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugues de promedicaments de pyrrolobenzodiazepine (pbd) pour le traitement de maladies
|
UA121775C2
(uk)
|
2015-07-31 |
2020-07-27 |
Пфайзер Інк. |
1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
|
US20180193335A1
(en)
*
|
2015-10-12 |
2018-07-12 |
Vikash J. BHAGWANDIN |
Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
|
CA3007595C
(fr)
|
2015-12-10 |
2020-08-25 |
Pfizer Limited |
Derives 4-(biphenyl-3-yl)-1h-pyrazolo[3,4-c]pyridazine de formule (i) utilises comme modulateurs de recepteur gaba pour le traitement de l'epilepsie et de la douleur
|
AR107132A1
(es)
|
2015-12-24 |
2018-03-21 |
Takeda Pharmaceuticals Co |
Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
|
KR20180105161A
(ko)
|
2016-01-07 |
2018-09-27 |
씨에스 파마테크 리미티드 |
Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
|
WO2017119732A1
(fr)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Dispositif électronique, et son procédé de fonctionnement
|
ES2837018T3
(es)
|
2016-01-15 |
2021-06-29 |
Pfizer |
Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
|
CN108884445A
(zh)
|
2016-03-09 |
2018-11-23 |
北京智康博药肿瘤医学研究有限公司 |
肿瘤细胞悬浮培养物和相关方法
|
CA2969295A1
(fr)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
|
EP3491005A1
(fr)
|
2016-07-29 |
2019-06-05 |
Pfizer Inc |
Peptides cycliques en tant qu'antagonistes du récepteur c5
|
MX2019001669A
(es)
|
2016-08-11 |
2019-09-27 |
Ovid Therapeutics Inc |
Metodos y composiciones para el tratamiento de trastornos epilepticos.
|
HUE055978T2
(hu)
|
2016-08-15 |
2022-01-28 |
Pfizer |
Piridopirimidinon CDK2/4/6 inhibitorok
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
WO2018134695A1
(fr)
|
2017-01-20 |
2018-07-26 |
Pfizer Inc. |
Dérivés de 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate utilisés comme inhibiteurs de la magl
|
KR20190097242A
(ko)
|
2017-01-23 |
2019-08-20 |
화이자 인코포레이티드 |
Magl 억제제로서의 헤테로시클릭 스피로 화합물
|
MX2019011286A
(es)
|
2017-03-26 |
2019-12-19 |
Takeda Pharmaceuticals Co |
Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6.
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
BR112019027127A2
(pt)
|
2017-06-22 |
2020-07-07 |
Curadev Pharma Limited |
moduladores de sting humano de molécula pequena
|
WO2019002889A1
(fr)
*
|
2017-06-30 |
2019-01-03 |
Industrial Technology Research Institute |
Procédé de traitement d'une maladie neurologique auto-immune et/ou d'une maladie neurodégénérative et formules pharmaceutiques pour une forme galénique liquide et une forme galénique à libération contrôlée
|
KR20200058411A
(ko)
|
2017-08-30 |
2020-05-27 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
|
US10435389B2
(en)
|
2017-09-11 |
2019-10-08 |
Krouzon Pharmaccuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
CN111788171A
(zh)
|
2018-01-29 |
2020-10-16 |
菲拓普兰特研究公司 |
使用液:液色谱法纯化大麻素的方法
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
TWI741268B
(zh)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
|
WO2019180072A1
(fr)
|
2018-03-22 |
2019-09-26 |
Bayer Pharma Aktiengesellschaft |
Composition pharmaceutique parentérale consistant en du bialanate de néladénoson
|
WO2019207463A1
(fr)
|
2018-04-26 |
2019-10-31 |
Pfizer Inc. |
Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
|
WO2019243823A1
(fr)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Modulateurs azahétérocycliques à petites molécules de sting humain
|
US20210309669A1
(en)
|
2018-07-19 |
2021-10-07 |
Pfizer Inc. |
Heterocyclic Spiro Compounds As MAGL Inhibitors
|
WO2020076728A1
(fr)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Oxazinoptéridinones substituées en tant qu'inhibiteurs de mtor
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
WO2020109994A1
(fr)
|
2018-11-29 |
2020-06-04 |
Pfizer Inc. |
Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
BR112021013019A2
(pt)
|
2019-01-23 |
2021-09-14 |
Pfizer Inc. |
Forma polimórfica de um sal de hidrato de monofosfato de um derivado de tetra-hidroisoquinolina conhecido
|
CU20210065A7
(es)
|
2019-01-31 |
2022-04-07 |
Pfizer |
Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
|
AR118471A1
(es)
|
2019-03-22 |
2021-10-06 |
Takeda Pharmaceuticals Co |
Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
|
KR20220012244A
(ko)
|
2019-04-29 |
2022-02-03 |
솔렌트 테라퓨틱스, 엘엘씨 |
Mrgx2의 억제제로서의 3-아미노-4h-벤조[e][1,2,4]티아디아진 1,1-디옥사이드 유도체
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
CA3147407A1
(fr)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Inhibiteurs a petites molecules de l'acetyl-coenzyme a synthetase a chaine courte 2 (acss2)
|
WO2021026124A1
(fr)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique
|
JOP20220063A1
(ar)
|
2019-09-16 |
2023-01-30 |
Takeda Pharmaceuticals Co |
مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول
|
GEP20237572B
(en)
|
2019-09-25 |
2023-11-27 |
Pfizer |
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
CN110538094B
(zh)
*
|
2019-09-27 |
2022-01-18 |
华南理工大学 |
一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
|
JP2023503928A
(ja)
|
2019-12-06 |
2023-02-01 |
マリナス ファーマシューティカルズ, インコーポレイテッド |
結節性硬化症の治療での使用のためのガナキソロン
|
CN110898015A
(zh)
*
|
2019-12-31 |
2020-03-24 |
上海汉维生物医药科技有限公司 |
一种伊曲康唑制剂的制备方法
|
JP2023513241A
(ja)
|
2020-02-12 |
2023-03-30 |
キュラデブ ファーマ ピーブイティー. リミテッド |
小分子stingアンタゴニスト
|
WO2021182951A1
(fr)
|
2020-03-10 |
2021-09-16 |
Seranovo Holding B.V. |
Plate-forme de formulation de solvant eutectique profond solide
|
NL2025092B1
(en)
*
|
2020-03-10 |
2021-10-19 |
Seranovo Holding B V |
Solid deep eutectic solvent formulation platform
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
WO2021220185A1
(fr)
|
2020-05-01 |
2021-11-04 |
Pfizer Inc. |
Composés d'azalactame utilisé en tant qu'inhibiteurs de hpk1
|
EP4121417A4
(fr)
*
|
2020-05-01 |
2023-08-09 |
University Of Southern California |
Thérapie antimicrobienne à base de cyclodextrine
|
IL297456A
(en)
|
2020-05-04 |
2022-12-01 |
Takeda Pharmaceuticals Co |
n-(piperidin-4-yl)benzamide derivatives are active in Nahor
|
WO2021224818A1
(fr)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Composés d'isoindolone en tant qu'inhibiteurs de hpk1
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018667A1
(fr)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Polythérapies utilisant des inhibiteurs de cdk2 et de cdc25a
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
US20220168272A1
(en)
*
|
2021-02-22 |
2022-06-02 |
Gholamhossein Yousefi |
Preparation of soluble form of carvedilol
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
CN113081989B
(zh)
*
|
2021-03-29 |
2022-10-21 |
海南普利制药股份有限公司 |
别嘌醇缓释片剂
|
MX2023011633A
(es)
|
2021-03-31 |
2023-12-15 |
Sevenless Therapeutics Ltd |
Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
CN117545751A
(zh)
|
2021-04-07 |
2024-02-09 |
生命爱科 |
作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
|
AU2022297733A1
(en)
|
2021-06-26 |
2024-01-04 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023017452A1
(fr)
|
2021-08-11 |
2023-02-16 |
Curadev Pharma Pvt. Ltd. |
Dérivés d'urée à petites molécules en tant qu'antagonistes de sting
|
IL310705A
(en)
|
2021-08-11 |
2024-04-01 |
Curadev Pharma Pvt Ltd |
Small molecule STING antagonists
|
WO2023099072A1
(fr)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Composés
|
WO2023187677A1
(fr)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Dérivés de n-(pyrrolidin-3-yl or pipéridin-4-yl)acétamide
|
WO2023194964A1
(fr)
|
2022-04-07 |
2023-10-12 |
Takeda Pharmaceutical Company Limited |
Dérivés de pyridazine fusionnés utilisés comme inhibiteurs de nlrp3
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(fr)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Composé hétérocyclique
|
CN115487080A
(zh)
*
|
2022-09-23 |
2022-12-20 |
山东博科医用材料有限公司 |
补骨脂酚微胶囊及其制备方法
|
WO2024074827A1
(fr)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
Nouveaux traitements de la douleur
|
WO2024105364A1
(fr)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Inhibiteurs hétérocycliques de kinases de type cdc
|